Peter J. O’Dwyer

Active 1985–2024

Also published as
Peter J O’Dwyer · Peter J. O'Dwyer
142
Papers
31,251
Citations
86
h-index
139
i10-index

Citations

Citations per year for Peter J. O’Dwyer1986: 3 citations1987: 4 citations1988: 3 citations1989: 5 citations1990: 10 citations1991: 10 citations1992: 10 citations1993: 12 citations1994: 19 citations1995: 22 citations1996: 43 citations1997: 38 citations1998: 44 citations1999: 51 citations2000: 51 citations2001: 38 citations2002: 49 citations2003: 52 citations2004: 61 citations2005: 82 citations2006: 105 citations2007: 191 citations2008: 201 citations2009: 226 citations2010: 237 citations2011: 367 citations2012: 424 citations2013: 433 citations2014: 407 citations2015: 408 citations2016: 397 citations2017: 379 citations2018: 343 citations2019: 859 citations2020: 1,095 citations2021: 1,193 citations2022: 914 citations2023: 741 citations2024: 976 citations2025: 476 citations2026: 15 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,560 citing papers, 32.1% of this breakdownChina: 1,348 citing papers, 9.5% of this breakdownItaly: 822 citing papers, 5.8% of this breakdownUnited Kingdom: 815 citing papers, 5.7% of this breakdownGermany: 693 citing papers, 4.9% of this breakdownFrance: 587 citing papers, 4.1% of this breakdownAustralia: 450 citing papers, 3.2% of this breakdownSpain: 434 citing papers, 3.1% of this breakdownJapan: 424 citing papers, 3% of this breakdownNetherlands: 404 citing papers, 2.8% of this breakdownCanada: 399 citing papers, 2.8% of this breakdownSwitzerland: 293 citing papers, 2.1% of this breakdown
0%32.1%Other 20.9%

Fields

  • Medicine55.3%
  • Biochemistry, Genetics and Molecular Biology32.2%
  • Immunology and Microbiology7.1%
  • Neuroscience1.1%
  • Engineering1.1%
  • Materials Science0.7%
  • Other2.5%

Topics

  • Pancreatic and Hepatic Oncology Research4.1%
  • Melanoma and MAPK Pathways3.9%
  • Cancer Immunotherapy and Biomarkers3.9%
  • Cancer Genomics and Diagnostics3.5%
  • Colorectal Cancer Treatments and Studies3.1%
  • Immune cells in cancer2.3%
  • Other79.2%

Coauthors

All papers

Open in search
  1. Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell 2014 cited by 1,137

  2. CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

    Authors: , , , , , , , , , , , , - Science 2011 cited by 1,661

  3. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 cited by 583

  4. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 296

  5. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

    Authors: , , , , , , , , , , - New England Journal of Medicine 2010 cited by 3,536

  6. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 693

  7. The NCI-MATCH trial: lessons for precision oncology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2023 cited by 183

  8. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 294

  9. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 295

  10. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2015 cited by 484

  11. Open-label, Phase I Study of Nivolumab Combined with nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 154

  12. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

    Authors: , , , , , , , , , , - Clinical Cancer Research 2017 cited by 318

  13. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer

    Authors: , , , , , , , , , , , , , - JAMA Oncology 2019 cited by 290

  14. Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

    Authors: , , , , , , , , , , , , , , - British Journal of Cancer 2023 cited by 74

  15. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

    Authors: , , , , , , , , , , , , , , , , - British Journal of Cancer 2019 cited by 170

  16. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

    Authors: , , , , , , , , , , , , , , , , , , , - Autophagy 2014 cited by 528

  17. Combined MTOR and autophagy inhibition

    Authors: , , , , , , , , , , , , , , , , , , , , - Autophagy 2014 cited by 419

  18. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

    Authors: , , , , , , , - Journal of Clinical Oncology 2007 cited by 2,272

  19. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 cited by 143

  20. Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 72

  21. A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

    Authors: , , , , , , , , , , - Clinical Cancer Research 2013 cited by 452

  22. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Worta McCaskill‐Stevens, Paolo F. Caimi, Naoko Takebe, Vivekananda Datta, Carlos L. Arteaga, Jeffrey S. Abrams, Robert L. Comis, Peter J O’Dwyer, Barbara A. Conley, for the NCI-MATCH Team - JNCI Journal of the National Cancer Institute 2020 cited by 228

  23. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 cited by 128

  24. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation

    Authors: , , , , , , , , , - British Journal of Cancer 2019 cited by 206